Literature DB >> 2921269

In vivo and in vitro test for growth potential of liver cells from rats during early stage of hepatocarcinogenesis by 3'-methyl-4-dimethylaminoazobenzene.

M Miyazaki1, S Wahid, J Sato.   

Abstract

A rapid increase in the fraction of small liver cells was observed in the liver of rats during the early stage of hepatocarcinogenesis by 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB). The change in cell population was represented by the decrease in glucose-6-phosphatase activity and by the increase in number of gamma-glutamyltranspeptidase-positive cells. When DNA synthesis of liver cells from rats fed 3'-Me-DAB was measured by autoradiography in primary culture, it began to increase 2 weeks after the start of the carcinogen feeding, reaching a plateau level after 3 weeks. Liver cells from rats fed 3'-Me-DAB for 2 weeks or over demonstrated a remarkable resistance to the cytotoxic effect of the carcinogen (0.24 mM) in primary culture. Furthermore, liver cells from rats fed 3'-Me-DAB for 3 weeks or over proliferated in the presence of the carcinogen in primary culture. When liver cells from 3'-Me-DAB-fed and control rats were transplanted into syngeneic rat spleens, the former cells proliferated more vigorously than did the latter. The growth potential of liver cells from 3'-Me-DAB-fed rats tended to be enhanced with time in the carcinogen feeding. Hepatocellular carcinomas developed in the host spleens implanted with liver cells from a rat fed 3'-Me-DAB for 8 weeks. As described above, liver cells from rats fed 3'-Me-DAB demonstrated much greater proliferative ability than normal control cells in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921269     DOI: 10.1007/BF00391592

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

1.  MORPHOLOGIC AND BIOLOGIC CORRELATION OF LESIONS OBTAINED IN HEPATIC CARCINOGENESIS IN A X C RATS GIVEN 0.025 PERCENT N-2-FLUORENYLDIACETAMIDE.

Authors:  M D REUBER; H I FIRMINGER
Journal:  J Natl Cancer Inst       Date:  1963-12       Impact factor: 13.506

2.  Cell kinetics of hepatocytes during the preneoplastic period of diethylnitrosamine-induced liver carcinogenesis.

Authors:  H M Rabes; R Szymkowiak
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

3.  Differences in growth of transplants of liver, liver hyperplastic nodules, and hepatocellular carcinomas in the mammary fat pad.

Authors:  G M Williams; M Klaiber; E Farber
Journal:  Am J Pathol       Date:  1977-11       Impact factor: 4.307

4.  Fluctuation of various cell populations and their characteristics during azo-dye carcinogenesis.

Authors:  T Iwasaki; K Dempo; A Kaneko; T Onoe
Journal:  Gan       Date:  1972-02

Review 5.  The sequential analysis of cancer development.

Authors:  E Farber; R Cameron
Journal:  Adv Cancer Res       Date:  1980       Impact factor: 6.242

6.  Initiation of chemical carcinogenesis requires cell proliferation.

Authors:  E Cayama; H Tsuda; D S Sarma; E Farber
Journal:  Nature       Date:  1978-09-07       Impact factor: 49.962

7.  The resistance of putative premalignant liver cell populations, hyperplastic nodules, to the acute cytotoxic effects of some hepatocarcinogens.

Authors:  E Farber; S Parker; M Gruenstein
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

8.  The persistence and phenotypic stability of transplanted rat liver neoplastic nodules.

Authors:  G M Williams; T Ohmori; K Watanabe
Journal:  Am J Pathol       Date:  1980-04       Impact factor: 4.307

9.  Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver.

Authors:  M Tatematsu; Y Nagamine; E Farber
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

10.  Repeated partial hepatectomy as a promoting stimulus for carcinogenic response of liver to nitrosamines in rats.

Authors:  A W Pound; L J McGuire
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.